Quince Therapeutics (NASDAQ: QNCX) shares Q3 2025 results and updates

Rhea-AI Filing Summary

Quince Therapeutics, Inc. filed a current report to note that it has announced its financial results for the quarter ended September 30, 2025 and shared recent business highlights. The company states that these details are contained in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 to this report rather than being fully included in the body of the document.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001662774false00016627742025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Quince Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38890	90-1024039
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
611 Gateway Boulevard Suite 273
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 910-5717

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Quince Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and provided recent business highlights. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued by Quince Therapeutics, Inc. dated November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			QUINCE THERAPEUTICS, INC.
Date:	November 12, 2025	By:	/s/ Dirk Thye
		Name: Title:	Dirk Thye Chief Executive Officer and Chief Medical Officer

FAQ

What did Quince Therapeutics (QNCX) report in this 8-K?

The company reported that it announced financial results for the quarter ended September 30, 2025 and provided recent business highlights through a press release furnished as Exhibit 99.1.

How did Quince Therapeutics disclose its Q3 2025 financial results?

Quince Therapeutics disclosed its quarterly financial results and recent business highlights in a press release dated November 12, 2025, which is attached to the report as Exhibit 99.1.

Are the Quince Therapeutics Q3 2025 numbers included in the 8-K text?

The report explains that the detailed financial results and business highlights are contained in the accompanying press release furnished as Exhibit 99.1, rather than in the main text.

What is Exhibit 99.1 in the Quince Therapeutics (QNCX) filing?

Exhibit 99.1 is the press release issued by Quince Therapeutics, Inc. on November 12, 2025 that contains the company’s financial results for the quarter ended September 30, 2025 and recent business highlights.

Is the Quince Therapeutics press release considered filed or furnished?

The report states that the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.